While Netflix and Meta stock shake off market volatility, Eli Lilly and this biotech stock join them and others on IBD ...

Wedbush reiterated its Outperform rating on Palantir with a $120 price target, stating, “We believe Palantir could be a ...

Palantir shares surged Monday as Wedbush analysts called it one their "top names" to own in 2025, expecting it to benefit from a "tidal wave of spending on AI." ...

The Dow Jones edged up in the stock market today. Warren Buffett issued a warning about the economy. Tesla stock rose on a bullish call.

The S&P 500 declined on Monday, continuing February’s losses as the approaching deadline for President Donald Trump’s tariff ...

Stocks erased morning gains and declined by afternoon on Monday as investors awaited President Donald Trump’s tariffs on ...

It rose 341% in just a year, and 2025 hasn't been so bad, either. It has risen around 20% so far this year, but at the time ...

What Happened? Shares of data-mining and analytics company Palantir (NYSE:PLTR) jumped 5.6% in the morning session after ...

Wall Street stocks largely climbed in early trading Monday, as the United States faces down a tariff deadline with fresh ...

The recent selloff in Palantir (PLTR) stock was misguided because the company’s “unique software value proposition” means it ...

Palantir is exhibiting strength as investors react to Wall Street's latest endorsement of the company's role as a key dfense ...

Now that a down February is in the rearview mirror, the markets breathed a sigh of relief but it didn’t last. After coming ...